Ultimovacs ASA Releases Financial Results for the Second Quarter of 2024
Today, Ultimovacs ASA (OSE ULTI), a biotechnology company focused on developing innovative immunotherapies for cancer, has announced its financial results for the second quarter of 2024.
Business Update for the Second Quarter of 2024
In response to recent clinical trial outcomes, Ultimovacs has implemented measures to preserve cash during the second quarter of 2024. These initiatives have successfully extended the expected cash runway into the fourth quarter of 2025, which coincides with the forthcoming topline results from the FOCUS and DOVACC trials.
Results from Clinical Trials
In August 2024, Ultimovacs released topline findings from the Phase II FOCUS trial, which focused on head and neck cancer. Unfortunately, the trial did not achieve its primary goal of improving progression-free survival (PFS), and the data did not show any enhancement in overall survival either. Nevertheless, the safety profile remained stable across all treatment groups, reaffirming UV1’s favorable safety profile. The significant findings from the FOCUS trial are slated for submission to a peer-reviewed medical journal for publication.
Research and Development Efforts
Ultimovacs is also concentrating on pre-clinical research centered around a new drug conjugation platform. This cutting-edge technology aims to bolster the expansion of their vaccine pipeline and broaden its applicability across various therapeutic areas. An update regarding this advancement is expected before the end of 2024.
Updates on Clinical Development
Current Trials
Ultimovacs is engaged in several promising clinical trials:
FOCUS (head and neck cancer): This trial investigates the combination of pembrolizumab with or without UV1 vaccination in adults suffering from metastatic or recurrent head and neck squamous cell carcinoma. Enrollment has concluded with a total of 75 patients, and topline results have recently been reported. The trial did not achieve its primary endpoint of improved PFS.
NIPU (mesothelioma): This trial evaluates ipilimumab and nivolumab with or without UV1 as a second-line treatment for inoperable malignant pleural mesothelioma, successfully enrolling 118 patients. Comprehensive results were shared at a significant oncology congress, indicating benefits for certain patient subgroups.
INITIUM (melanoma): This study assesses ipilimumab and nivolumab in conjunction with UV1 for unresectable or metastatic melanoma. Enrollment has concluded with 156 patients, but the trial did not meet its primary endpoints. Selected results were recently presented.
INITIUM Supplementary Study: This study is investigating UV1's biological activity alongside standard treatments, with results anticipated soon.
DOVACC (ovarian cancer): Currently, 184 patients are being enrolled, with results expected in the near future.
LUNGVAC (non-small cell lung cancer): This trial is also in progress, with patient enrollment moving forward effectively.
Financial Overview
In light of recent challenges, Ultimovacs has made financial sustainability a priority, achieving notable cash savings. The cash runway is projected to last until at least the fourth quarter of 2025. Recent operational adjustments include a workforce reduction, with ongoing efforts to manage expenses efficiently. Operating expenses amounted to MNOK 45.3 during Q2 2024, while total losses reached MNOK 44.8.
Cash Flow and Financial Assets
As of the end of June 2024, the company reported cash and cash equivalents of MNOK 170.4. A detailed quarterly financial report will be available soon on the company's website.
About Ultimovacs
Ultimovacs is an innovative clinical-stage biotechnology company committed to developing groundbreaking immunotherapies for cancer treatment. The company is particularly focused on its candidate UV1, a therapeutic cancer vaccine designed to enhance the effectiveness of immunotherapy for patients. This vaccine stimulates immune responses against the telomerase antigen, which is present in various types of cancer. Ultimovacs is actively conducting multiple cancer trials at international sites, engaging over 750 patients.
Frequently Asked Questions
What were the key highlights from the Q2 2024 report?
Ultimovacs emphasized cash preservation strategies and the outcomes of the Phase II FOCUS trial, which did not meet its primary endpoints.
Which trials are currently being conducted by Ultimovacs?
Ultimovacs is conducting several trials, including those focused on head and neck cancer, melanoma, mesothelioma, ovarian cancer, and non-small cell lung cancer.
How have the financial results impacted Ultimovacs' operations?
To extend the cash runway, Ultimovacs has made operational adjustments and prioritized financial sustainability in light of recent challenges.
What innovative technologies is Ultimovacs pursuing?
Ultimovacs is developing a new drug conjugation platform aimed at enhancing its vaccine pipeline and expanding into additional therapeutic areas.
How can I get in touch with Ultimovacs for more information?
For inquiries, please contact Carlos de Sousa, CEO, at carlos.desousa@ultimovacs.com or +47 908 92507.
